Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Hyman

Showing results (91-100 of 174) with videos related to

Pageof 18
Sort By:
Cancer Chemotherapy and Pharmacology|February 13, 2015
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumorsDavid M Hyman, Alexandra E Snyder, Richard D Carvajal, et al.
JAMA Oncology|November 12, 2015
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNAKasmintan A Schrader, Donavan T Cheng, Vijai Joseph, et al.
Gynecologic Oncology|November 25, 2018
Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockadeJulia L Boland, Qin Zhou, Madhuri Martin, et al.
Nature|March 15, 2019
Efficacy of MEK inhibition in patients with histiocytic neoplasmsEli L Diamond, Benjamin H Durham, Gary A Ulaner, et al.
Nature Medicine|December 19, 2018
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signalingZhan Yao, Yijun Gao, Wenjing Su, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2018
BRAF Inhibition in <i>BRAF</i><sup>V600</sup>-Mutant Gliomas: Results From the VE-BASKET StudyThomas Kaley, Mehdi Touat, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway AlterationsElio Adib, Katarzyna Klonowska, Krinio Giannikou, et al.
Science (New York, N.Y.)|December 9, 2017
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapyDiego Chowell, Luc G T Morris, Claud M Grigg, et al.
Cancer Discovery|February 10, 2019
Correction: An Acquired <i>HER2</i> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast CancerAriella B Hanker, Monica Red Brewer, Jonathan H Sheehan, et al.
Cancer Discovery|March 10, 2017
An Acquired <i>HER2</i><sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast CancerAriella B Hanker, Monica Red Brewer, Jonathan H Sheehan, et al.
Pageof 18

Showing results (91-100 of 174) with videos related to

Sort By:
Pageof 18
Cancer Chemotherapy and Pharmacology|February 13, 2015
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumorsDavid M Hyman, Alexandra E Snyder, Richard D Carvajal, et al.
JAMA Oncology|November 12, 2015
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNAKasmintan A Schrader, Donavan T Cheng, Vijai Joseph, et al.
Gynecologic Oncology|November 25, 2018
Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockadeJulia L Boland, Qin Zhou, Madhuri Martin, et al.
Nature|March 15, 2019
Efficacy of MEK inhibition in patients with histiocytic neoplasmsEli L Diamond, Benjamin H Durham, Gary A Ulaner, et al.
Nature Medicine|December 19, 2018
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signalingZhan Yao, Yijun Gao, Wenjing Su, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2018
BRAF Inhibition in <i>BRAF</i><sup>V600</sup>-Mutant Gliomas: Results From the VE-BASKET StudyThomas Kaley, Mehdi Touat, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway AlterationsElio Adib, Katarzyna Klonowska, Krinio Giannikou, et al.
Science (New York, N.Y.)|December 9, 2017
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapyDiego Chowell, Luc G T Morris, Claud M Grigg, et al.
Cancer Discovery|February 10, 2019
Correction: An Acquired <i>HER2</i> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast CancerAriella B Hanker, Monica Red Brewer, Jonathan H Sheehan, et al.
Cancer Discovery|March 10, 2017
An Acquired <i>HER2</i><sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast CancerAriella B Hanker, Monica Red Brewer, Jonathan H Sheehan, et al.
Pageof 18